An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment - CASTING

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: d9c29efcf02a23a92e03287a3e20ba501995930b
First added on: Apr 17, 2025